Current status, problems, and perspectives of non-alcoholic fatty liver disease research

doi:10.3748/wjg.v25.i2.163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14647)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

1363

WORD

345

HTML

8906

Tables (1-4)

240

Sum=10854

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

680

Download

609

Sum=1289

Publishing Process of This Article

Item

Count

Browse

1138

Download

1366

Sum=2504

Jan 14, 2019 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (110)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 14, 2019; 25(2): 163-177
Published online Jan 14, 2019. doi: 10.3748/wjg.v25.i2.163

Table 3 Novel therapeutic agents for non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis under clinical trials

Target	Agent	Action	Clinical trial
Diabetes, insulin resistance	Semaglutide	DPP4 inhibitor	Phase II
	Gliflozin	SGLT2 inhibitor[89]	Pilot
	BMS-986036	Recombinant FGF21[90]	Phase II
Dyslipidemia	Aramchol	SCD inhibitor	Phase II
Dyslipidemia	GS-0976	ACC inhibitor	Phase II
Nuclear receptor	Obeticholic acid	FXR agonist[84]	Phase III
	Elafibranor	PPARα/δ agonist[85]	Phase III
	MGL-3196	TRβ agonist	Phase II
Apoptosis	Emricasan	Pan-caspase inhibitor[91]	Phase II
Inflammation, fibrosis	Selonsertib	ASK1 inhibitor[87]	Phase III
	Cenicriviroc	CCR2/5 antagonist[88]	Phase III
	JKB-121	TLR4 antagonist	Phase II
	GR-MD-02	Galectin 3 inhibitor[92]	Phase II
	ND-LO2-s0201	HSP47 siRNA[93]	Phase I

Citation: Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 2019; 25(2): 163-177
URL: https://www.wjgnet.com/1007-9327/full/v25/i2/163.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i2.163